Rockville biotech Shuttle Pharma inks deal to advance key drug - Washington Business Journal

Published on 10 Mar 2023 on The Business Journals

Welcome to Bio Briefing, a weekly rundown of the biggest moves in Greater Washington's biotech...

Read the rest of the article

Start tracking your investments with Statfolio

Stuart Peters, Senior VP and General Counsel at MacroGenics Inc (NASDAQ:MGNX), sold a significant...

Investing.com 9 Apr 2024

Investment analysts have revised their price targets upwards for six major stocks this week, with...

Benzinga 5 Apr 2024

Wednesday, MacroGenics Inc MGNX provided an update on the Phase 2 TAMARACK study of vobramitamab ...

Benzinga 5 Apr 2024

U.S. stock futures were higher this morning, with the Dow futures gaining by around 90 points on ...

Benzinga 4 Apr 2024

MacroGenics (MGNX) stock rises after positive interim data from its Phase 2 TAMARACK study for it...

Seeking Alpha 4 Apr 2024

MacroGenics, Inc. (NASDAQ:MGNX) Q4 2023 Earnings Call Transcript March 7, 2024 MacroGenics, Inc. ...

Insider Monkey via Yahoo Finance 14 Mar 2024

Cash Position: Increased to $229.8 million as of December 31, 2023, from $154.3 million the previ...

GuruFocus.com via Yahoo Finance 7 Mar 2024

MacroGenics (MGNX) came out with a quarterly loss of $0.75 per share versus the Zacks Consensus E...

Zacks via Yahoo Finance 7 Mar 2024

Eric Risser, the Chief Operating Officer of Macrogenics Inc (NASDAQ:MGNX), has sold 41,159 shares...

GuruFocus.com via Yahoo Finance 6 Mar 2024

Key Insights MacroGenics' estimated fair value is US$36.82 based on 2 Stage Free Cash Flow to Equ...

Simply Wall St. via Yahoo Finance 2 Mar 2024